This study is testing a medicine called lerodalcibep (300 mg given monthly as a shot under the skin) in children aged 6 to 17 years who have heterozygous familial hypercholesterolemia (HeFH), an inherited condition causing very high cholesterol. The main goal is to see how well lerodalcibep lowers "bad" cholesterol (LDL-C) after 12 weeks, compared to a dummy shot (placebo). Researchers also want to understand if it's safe and how well children tolerate it. You might be able to join if you are 6 to 17 years old, weigh over 40 lbs, and have HeFH while already taking cholesterol-lowering medicines like statins. The study is currently recruiting about 150 participants.

Study design

This is a randomized, placebo-controlled, double-blind study, meaning participants are randomly assigned to receive either lerodalcibep or a placebo, and neither you nor your doctor will know which you are receiving. Approximately 150 participants will be enrolled.

What's involved

The total study duration will be up to 35 weeks, including a screening period of up to 11 weeks and 24 weeks of treatment. You will have clinic visits monthly for 20 weeks, then at weeks 22 and 24.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for measuring LDL cholesterol is at Week 12, and the treatment period lasts 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.